These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32596715)

  • 1. Prognostic implications of programmed death ligand 1 expression in resected lung adenocarcinoma: a systematic review and meta-analysis.
    Chen D; Mao Y; Ding Q; Wang W; Zhu F; Chen C; Chen Y
    Eur J Cardiothorac Surg; 2020 Nov; 58(5):888-898. PubMed ID: 32596715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K
    Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
    Song Z; Yu X; Cheng G; Zhang Y
    J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
    Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
    Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
    J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
    Guo CY; Zhu Q; Tou FF; Wen XM; Kuang YK; Hu H
    BMC Cancer; 2019 Mar; 19(1):289. PubMed ID: 30925904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression in resected lung adenocarcinoma: prevalence and prognostic significance in relation to the IASLC grading system.
    Hwang S; Hong TH; Kim HK; Cho J; Lee G; Choi S; Park S; Lee SH; Lee Y; Jeon YJ; Lee J; Park SY; Cho JH; Choi YS; Kim J; Zo JI; Shim YM; Choi YL
    Histopathology; 2024 May; 84(6):1013-1023. PubMed ID: 38288635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.
    Matikas A; Zerdes I; Lövrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T
    Clin Cancer Res; 2019 Sep; 25(18):5717-5726. PubMed ID: 31227501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
    Wu S; Shi X; Sun J; Liu Y; Luo Y; Liang Z; Wang J; Zeng X
    Oncotarget; 2017 Mar; 8(10):16421-16429. PubMed ID: 28145884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
    Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
    Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients.
    Qin T; Xia J; Liu S; Wang J; Liu H; Zhang Y; Jia Y; Li K
    Thorac Cancer; 2020 May; 11(5):1139-1148. PubMed ID: 32154654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2014 May; 50(7):1361-9. PubMed ID: 24548766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
    Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
    Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
    Shen M; Jiang K; Sui Y; Xu Z; Cui H; Wang Y; Zhang H; Xu Z; Xu W; Ding Q; Chen Y
    Lung Cancer; 2021 Oct; 160():84-91. PubMed ID: 34479175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.
    Toyokawa G; Takada K; Tagawa T; Hamamoto R; Yamada Y; Shimokawa M; Oda Y; Maehara Y
    Ann Thorac Surg; 2019 Feb; 107(2):393-400. PubMed ID: 30343006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of programmed death-ligand 1 expression in resected lung cancer and its relationship with EGFR mutation.
    Osoegawa A; Abe M; Takumi Y; Hashimoto T; Karashima T; Miyawaki M; Sugio K
    Thorac Cancer; 2023 Aug; 14(24):2467-2472. PubMed ID: 37455369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.